Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?
Nurix Therapeutics Ownership Summary
Nurix Therapeutics is owned by 92.84% institutional investors, 1.45% insiders, and 5.71% retail investors. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. ARK Genomic Revolution is the top mutual fund, with 3.28% of its assets in Nurix Therapeutics shares.
NRIX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Nurix Therapeutics | 92.84% | 1.45% | 5.71% |
| Sector | Healthcare Stocks | 49.73% | 8.84% | 41.43% |
| Industry | Biotech Stocks | 47.04% | 8.74% | 44.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 6.82M | 12.42% | $142.33M |
| Redmile group | 4.42M | 8.06% | $92.32M |
| Deep track capital, lp | 3.99M | 7.27% | $83.30M |
| Baker bros. advisors lp | 3.88M | 7.07% | $81.02M |
| Vanguard group | 3.63M | 6.60% | $75.65M |
| Wellington management group llp | 3.20M | 5.83% | $66.82M |
| Price t rowe associates inc /md/ | 2.84M | 5.16% | $59.17M |
| State street | 2.71M | 4.93% | $56.53M |
| Ark investment management | 2.32M | 4.23% | $48.49M |
| T. rowe price investment management | 2.19M | 3.99% | $45.69M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Redmile group | 4.42M | 5.58% | $92.32M |
| Soleus capital management | 2.06M | 3.78% | $42.91M |
| Deep track capital, lp | 3.99M | 2.49% | $83.30M |
| Affinity asset advisors | 912.00K | 2.19% | $19.03M |
| Opaleye management | 418.93K | 2.00% | $8.74M |
| Ikarian capital | 440.50K | 1.60% | $9.19M |
| Westhill financial advisors | 283.33K | 1.43% | $5.91M |
| Parkman healthcare partners | 474.68K | 1.33% | $9.91M |
| Stempoint capital lp | 203.27K | 1.25% | $4.24M |
| Baker bros. advisors lp | 3.88M | 1.04% | $81.02M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Wellington management group llp | 3.20M | 0.01% | 2.97M |
| Blackrock | 6.82M | 0.00% | 2.24M |
| T. rowe price investment management | 2.19M | 0.03% | 2.19M |
| Driehaus capital management | 1.28M | 0.26% | 1.28M |
| Vanguard group | 3.63M | 0.00% | 1.04M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Bain capital life sciences investors | - | - | -1.13M |
| Ra capital management | - | - | -650.00K |
| Morgan stanley | 1.99M | 0.00% | -541.10K |
| Deutsche bank ag\ | 1.05M | 0.01% | -450.97K |
| Wasatch advisors lp | 858.07K | 0.10% | -378.69K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| T. rowe price investment management | 2.19M | 0.03% | 2.19M | $45.69M |
| Driehaus capital management | 1.28M | 0.26% | 1.28M | $26.78M |
| Samlyn capital | 583.49K | 0.20% | 583.49K | $12.18M |
| Norges bank | 507.54K | 0.00% | 507.54K | $10.59M |
| Vestal point capital, lp | 500.00K | 0.78% | 500.00K | $10.44M |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -9.00 |
| Comerica bank | -96.00 |
| Macroview investment management | -360.00 |
| Mark sheptoff financial planning | -400.00 |
| Pacer advisors | -781.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 174 | -1.14% | 67,568,477 | 3.95% | 92 | 0.66% | 94 | -16.81% | 56 | 24.44% |
| Jun 30, 2024 | 175 | 24.11% | 64,997,079 | 32.92% | 118 | 1.49% | 112 | 60.00% | 45 | 4.65% |
| Mar 31, 2024 | 141 | 6.82% | 48,899,624 | 6.46% | 89 | 1.25% | 70 | 2.94% | 43 | 10.26% |
| Dec 31, 2023 | 132 | 0.76% | 45,933,203 | 2.43% | 84 | 1.24% | 68 | 23.64% | 39 | -23.53% |
| Sep 30, 2023 | 131 | 1.55% | 44,845,099 | 2.77% | 82 | 1.26% | 55 | -9.84% | 51 | 18.60% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ARK Genomic Revolution | 2.20M | 3.28% | -95.17K |
| ARK Genomic Revolution ETF | 2.10M | 2.97% | 6.18K |
| Vanguard Total Stock Mkt Idx Inv | 2.04M | 2.88% | -89.69K |
| iShares Russell 2000 ETF | 1.64M | 2.32% | -3.70K |
| T. Rowe Price New Horizons | 1.45M | 2.17% | -4.58K |
| US Small-Cap Growth II Equity Comp | 1.45M | 2.17% | -5.17K |
| SPDR® S&P Biotech ETF | 1.03M | 1.46% | 11.42K |
| Pictet-Biotech P USD | 989.28K | 1.40% | 308.79K |
| Vanguard Institutional Extnd Mkt Idx Tr | 906.47K | 1.28% | -2.65K |
| Belfius Equities Cure C Cap | 624.82K | 0.93% | -142.28K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 02, 2024 | Ring Christine | Chief Legal Officer | Sell | $125.16K |
| Nov 04, 2024 | Ring Christine | Chief Legal Officer | Sell | $82.25K |
| Nov 01, 2024 | Ring Christine | Chief Legal Officer | Sell | $139.87K |
| Nov 01, 2024 | van Houte Hans | Chief Financial Officer | Sell | $86.08K |
| Oct 30, 2024 | van Houte Hans | Chief Financial Officer | Sell | $57.55K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q4 | - | 10 |
| 2024 Q3 | - | 13 |
| 2024 Q2 | - | 9 |
| 2024 Q1 | - | 4 |
| 2023 Q4 | - | 5 |
NRIX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools